Ioxaglic Acid

CHEMBL1201291 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1268.9 g/mol
LogP
2.8
Phase
4

This iodinated contrast agent is a low-osmolality ionic compound (ionic dimer) used for intravascular procedures including coronary angiography and venography. Its lower osmolality compared to older ionic monomeric agents reduces cardiovascular stress and patient discomfort. It was among the first low-osmolality contrast agents developed.

Berat Molekul

1268,9000 g/mol

LogP

2,80

TPSA

194,00 Ų

Lipinski RO5

Gagal

Mekanisme Kerja

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CNC(=O)c1c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c2I)c(I)c(N(C)C(C)=O)c1I

InChI

InChI=1S/C24H21I6N5O8/c1-7(37)35(3)20-17(29)10(21(39)31-2)13(25)11(18(20)30)23(41)33-6-8(38)34-19-15(27)9(22(40)32-4-5-36)14(26)12(16(19)28)24(42)43/h36H,4-6H2,1-3H3,(H,31,39)(H,32,40)(H,33,41)(H,34,38)(H,42,43)

Molecular Formula

C24H21I6N5O8

HBD / HBA

6 / 8

Ikatan yang Dapat Dirotasi

10

Atom Berat

43

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This iodinated contrast agent is a low-osmolality ionic compound (ionic dimer) used for intravascular procedures including coronary angiography and venography. Its lower osmolality compared to older ionic monomeric agents reduces cardiovascular stress and patient discomfort. It was among the first low-osmolality contrast agents developed.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Ioxaglic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201291. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3742. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.